TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments – Seeking Alpha
Seeking Alpha |
TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments
Seeking Alpha The company is developing promising stem cell treatments for perianal fistulae and cardiac disease heart repair. It needs to address major objections to its lead candidate by the EMA and further advance its cardiac disease treatment. My opinion is … |
